

Robust Base; Near-term Revlimid Pressure

Est. Vs. Actual for Q1FY26: Revenue – **MISS**; EBITDA – **MISS**; PAT – **MISS**

Changes in Estimates post Q1FY26

FY26E/FY27E: Revenue: -0.7%/-0.9%; EBITDA: -0.7%/-0.9%; PAT: -0.9%/-1.2%

Recommendation Rationale:

- **Q1FY26 Miss; US Weakness Offsets Emerging Market Gains:** Aurobindo reported revenue of Rs 7,868 Cr in Q1FY26, missing our estimates. Revenue grew by 4% YoY but declined 6.1% QoQ, primarily due to a drop in gRevlimid sales in the US and price erosion in the API segment. Despite the headwinds, performance was supported by momentum in Europe and growth markets, along with an incremental contribution from the ARV market.
- **EBITDA Margins Decline; FY26 Guidance Remains Intact:** Gross margins were impacted by 28 bps QoQ and by 56 bps YoY. EBITDA margins decreased by 100 bps YoY and QoQ. EBITDA stood at Rs 1,603 Cr with a 20.4% margin, and excluding gRevlimid, EBITDA grew 12% YoY. Management guided for a 20–21% EBITDA margin in FY26, backed by mix optimisation and efficiency gains.
- **Capex Done; Ramp-Up Next:** The company has invested Rs 7,000 Cr in the last 2-3 years toward biosimilars, Pen-G, and US/China plants. With no major greenfield capex ahead, commercial ramp-up is expected to drive ROIC and valuations.

Sector Outlook: Positive

Company Outlook & Guidance: Aurobindo Pharma remains confident in sustaining its growth momentum in FY26. It targets high single-digit revenue growth (excluding one-offs), with continued strength in Europe and North America. The company aims to maintain EBITDA margins at 20–21%, supported by a favourable product mix, stable input costs, and operational efficiencies. Over the past two years, Rs 7,000 Cr has been invested in biosimilars and Pen-G (API), with future valuations expected to hinge on returns from these investments. Margin expansion will be further supported by the injectables and biosimilars scale-up and contributions from the Lannett acquisition. Strategic investments in CMO and biologics are expected to fuel long-term growth. Importantly, no new greenfield capex is planned for the next three years, reflecting a focus on optimising existing assets.

Current Valuation: PE 18x for 1HFY27E Earnings (Earlier Valuation: PE 20x/FY26E)

Current TP: Rs 1,400/share (Earlier TP: Rs 1,500/share)

Recommendation: BUY

Financial Performance

Aurobindo Pharma's Q1FY26 results came in below our expectations. The company reported a revenue of Rs 7,868 Cr, up 4% YoY but down 6.1% QoQ. This was due to a drop in gRevlimid sales in the US and price erosion in the API segment. Despite the headwinds, performance was supported by momentum in Europe and growth markets, along with incremental Contribution from the ARV market.

Key Financials (Consolidated)

(Rs Cr)	Q1FY26	QoQ (%)	YoY (%)	Axis Est.	Variance
Net Sales	7,868	-6.1	4.0	8,302	-5.2
EBITDA	1,603	2.4	-1.0	1,816	-11.7
EBITDA Margin	20.4%	28	-103	21.9%	
Net Profit	824	0.9	-10.3	972	-15.2
EPS (Rs)	14.2	0.9	-10.3	16.6	-14.6

Source: Company, Axis Securities Research

(CMP as of 05th August, 2025)

CMP (Rs)	1,080
Upside /Downside (%)	30%
High/Low (Rs)	1,592/1,010
Market cap (Cr)	62,680
Avg. daily vol. (6m)Shrs.	3,00,000
No. of shares (Cr)	58.08

Shareholding (%)

	Dec-24	Mar-25	Jun-25
Promoter	51.8	51.8	51.8
FII	16.3	15.3	14.4
MFs / UTI	17.8	18.2	19.0
Others	14.1	14.6	14.8


Financial & Valuations

Y/E Mar (Rs Cr)	FY25	FY26E	FY27E
Net Sales	31,724	34,335	38,266
EBITDA	6,583	7,554	8,610
Net Profit	3,484	4,321	4,885
EPS (Rs)	60.0	74.4	84.1
PER (x)	18.0	14.5	12.8
EV/EBITDA (x)	9.5	7.9	6.6
P/BV (x)	1.9	1.7	1.5
ROE (%)	10.7	11.8	11.8

Change in Estimates (%)

Y/E Mar	FY26E	FY27E
Sales	-0.7%	-0.9%
EBITDA	-0.7%	-0.9%
PAT	-0.9%	-1.2%

Relative Performance



Source: Ace Equity

Aman Goyal
Research Associate
aman.goyal@axissecurities.in

Financial Performance (Cont'd)

In North America, Aurobindo recorded revenue of \$408 Mn (4.3% YoY degrowth in constant currency), with an estimated \$30 Mn contribution from gRevlimid. The decline was driven by gRevlimid erosion, seasonal moderation, and inventory destocking. Despite this, injectable sales rose 11% QoQ, aided by 15 new launches.

Europe maintained its growth momentum with a 9% YoY rise to €241 Mn, putting the company on track to cross €1 Bn in annual revenue by FY26-end. API revenues fell 16% YoY to Rs 916 Cr, impacted by pricing pressure and rising import competition. ARV segment posted strong 55% YoY growth, supported by tender wins and volume uptick. Growth markets rose 9% to Rs 772 Cr.

EBITDA stood at Rs 1,603 Cr, with margins at 20.4%, impacted by a sharp drop in gRevlimid contribution. However, adjusted for gRevlimid, EBITDA grew 12% YoY, highlighting strong operational resilience. R&D spend was Rs 367 Cr (4.7% of sales), reflecting continued focus on complex generics and biosimilars.

Capex for the quarter stood at Rs 610 Cr (\$73 Mn), primarily directed toward biosimilars and new facility expansion. A net cash inflow of Rs 819 Cr (\$98 Mn) boosted the company's net cash position to Rs 1,170 Cr (\$140 Mn), while gross debt declined to Rs 7,380 Cr (\$884 Mn). PAT for the quarter was Rs 824 Cr.

Upcoming Pipelines and Growth Drivers: Aurobindo resumed operations at its Pen-G manufacturing facility in Jul'25 following regulatory clearance, with early signs of improved yields and output. The company received EU approvals for its biosimilar portfolio, with commercial launches expected to begin in H2FY26. Revenue contribution from both Pen-G and biosimilars is expected to start from Q3/Q4FY26. Additionally, the China facility has already commenced invoicing during Q1FY26, while the US-based Dayton site remains a key near-term growth driver, currently awaiting regulatory approval.

Outlook

Growth Momentum and Margin Resilience to Drive FY26 Performance

Aurobindo Pharma remains optimistic about sustaining its growth trajectory in FY26, aiming for high single-digit revenue growth (excluding one-offs) with continued momentum in Europe and North America. The company also intends to maintain EBITDA margins around 21%, supported by a favourable product mix, stable raw material costs, and improved efficiencies.

Strengthens Manufacturing and Complex Generics Capabilities

Capacity Expansion continues to be a key focus, with the China OST plant now commercialised and expected to contribute meaningfully in FY26. The US-based Dayton OST facility is scheduled for commercial launch later this year, and the Raleigh plant is set to become fully operational soon, expanding into transdermal and respiratory therapies. Aurobindo is also building a robust pipeline in complex generics, including a respiratory partnership with a global pharma major.

Biosimilars and Pen-G Revival to Support Long-Term Growth

In the biosimilars segment, the company is making steady progress with recent approvals and pipeline advancement, particularly in regulated markets. The Penicillin-G plant in Kakinada, previously halted due to a fire, is expected to resume post regulatory clearance, having earlier demonstrated promising yields. Management remains confident in the growth potential of biosimilars and Pen-G, underpinned by ongoing investments, compliance, and capacity expansion.

Valuations & Recommendation

Aurobindo Pharma's future outlook remains strong, supported by upcoming product launches and strategic initiatives in areas such as entry into Biosimilars, peptides, and CDMO services. **We maintain our BUY recommendation on the stock with a TP of Rs 1,400/share.**

Key Risks to Our Estimates and TP

- The USFDA inspection and issuing of WL/OAI or 483 observations may impact the revenue growth.
- Entry of new players may increase pricing pressures in the injectable portfolio.
- Delay in the launch of Biosimilars in the market.

Change in Estimates

(Rs Cr)	New		Old		% Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Sales	34,335	38,266	34,563	38,626	-0.7%	-0.9%
EBITDA	7,554	8,610	7,604	8,691	-0.7%	-0.9%
PAT	4,321	4,885	4,358	4,943	-0.9%	-1.2%

Source: Company, Axis Securities Research

Results Review

Particulars (Rs Cr)	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY (%)	QoQ (%)
Sales	7,567	7,796	7,979	8,382	7,868	4.0	-6.1
Other Operating Income	0	0	0	0	0		
Net Sales	7,567	7,796	7,979	8,382	7,868	4.0	-6.1
Growth (%)	10.5%	8.0%	8.5%	10.6%	4.0%		
Total Expenditure	5,947	6,230	6,401	6,590	6,265	5.3	-4.9
Raw Material Consumed	3,073	3,210	3,315	3,428	3,239	5.4	0.9
% of sales	40.6%	41.2%	41.6%	40.9%	41.2%		
Gross margins %	59.4%	58.8%	58.4%	59.1%	58.8%	-56	1
Employee Expenses	1,072	1,109	1,132	1,163	1,229	14.6	10.8
% of sales	14.2%	14.2%	14.2%	13.9%	15.6%		
Forex	0	0	50	0	0		
Other Expenses	1,803	1,910	1,904	2,000	1,797	6.0	6.0
% of sales	23.8%	24.5%	23.9%	23.9%	22.8%		
EBITDA	1,620	1,566	1,578	1,792	1,603	-1.0	2.4
EBITDAM (%)	21.4%	20.1%	19.8%	21.4%	20.4%	-103	28
Interest	111	113	118	115	98		
Depreciation	404	382	419	444	406		
Share of JV	-1	0	2	-32	2		
Exceptional Items	0	0	0	0	0		
Other Income	221	136	157	135	105		
PBT	1,324	1,207	1,200	1,335	1,207	-8.9	-0.0
Tax	406	391	354	432	383		
Tax (%)	30.6%	32.3%	29.5%	32.4%	31.7%		
Reported PAT	919	817	846	903	824	-10.3	0.9

Source: Company, Axis Securities Research

Geographical Breakup

Particulars (Rs Cr)	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY (%)	QoQ (%)
USA	3,555	3,530	3,671	4,072	3,488	-1.9	-14.3
EU	1,982	2,105	2,121	2,147	2,338	18.0	8.9
Growth markets	709	812	873	786	772	8.9	-1.8
ARV	229	193	307	306	355	55.0	16.0
Betalactum	791	837	722	789	633	-20.0	-19.8
Non Betalactum	321	319	284	280	283	-11.8	1.1

Source: Company, Axis Securities Research

Financials (consolidated)

Profit & Loss

(Rs Cr)

Y/E Mar, Rs Cr	FY25	FY26E	FY27E	FY28E
Net Sales	31,724	34,335	38,266	42,921
Growth (%)	9.4%	8.2%	11.4%	12.2%
Total Expenditure	25,141	26,781	29,656	33,092
Raw Material Consumed	13,026	14,421	16,072	18,027
% of sales	41.1%	42.0%	42.0%	42.0%
Gross margins (%)	58.9%	58.0%	58.0%	58.0%
Employee Expenses	4,476	4,807	5,166	5,837
% of sales	14.1%	14.0%	13.5%	13.6%
Other Expenses	7,639	7,554	8,418	9,228
% of sales	24.1%	22.0%	22.0%	21.5%
EBIDTA	6,583	7,554	8,610	9,829
EBITDAM (%)	20.8%	22.0%	22.5%	22.9%
Depreciation	1,649	1,779	1,923	2,019
EBIT	4,933	5,774	6,687	7,810
EBITM (%)	15.6%	16.8%	17.5%	18.2%
Interest	457	454	412	370
Other Income	622	460	500	500
Exceptional Items	0	0	0	0
Share of P/L of Associates	-32	-20	10	10
PBT	5,066	5,761	6,785	7,950
Tax Rate (%)	31.2%	25.0%	28.0%	28.0%
Tax	1,583	1,440	1,900	2,226
Reported PAT	3,484	4,321	4,885	5,724

Source: Company, Axis Securities Research

Balance Sheet

(Rs Cr)

Y/E Mar, Rs Cr	FY25	FY26E	FY27E	FY28E
Share Capital	58	58	58	58
Reserves & Surplus	32,589	36,646	41,267	46,728
Shareholders Fund	32,647	36,704	41,325	46,786
Total Debt	8,263	7,563	6,863	6,163
- Deferred Tax (Net)	2,456	2,262	2,101	1,947
- Trade Payables	4,189	4,703	5,242	5,880
Provisions	14,682	15,174	15,697	16,409
Others	49,785	54,140	59,123	65,142
Total Liabilities	1.6	1.5	1.6	1.7
Gross Block	2,284	1,800	1,800	1,200
Depreciation	20,440	22,240	24,040	25,240
% of GB	8,545	10,324	12,248	14,267
Net Block	41.8%	46.4%	50.9%	56.5%
CWIP	11,895	11,916	11,793	10,973
- Fixed Assets	3,266	3,266	3,266	3,266
Investment	22,623	22,851	23,081	22,681
- Deferred Tax (Net)	0	0	0	0
Loans & Advances	10,544	11,288	12,580	14,111
Others	5,746	6,020	6,710	7,526
- Inventories	8,235	10,672	13,067	16,693
- Trade Receivables	2,622	3,292	3,669	4,116
- Cash	27,162	31,289	36,042	42,461
Total Assets	49,785	54,140	59,123	65,142

Source: Company, Axis Securities Research

Cash Flow

(Rs Cr)

Y/E Mar, Rs Cr	FY25	FY26E	FY27E	FY28E
PBT	5,066	5,761	6,785	7,950
Add: Depreciation	1,649	1,779	1,923	2,019
Add: Interest	457	454	412	370
Cash flow from operations	7,173	7,994	9,120	10,339
Change in working capital	1,524	899	1,650	1,954
Taxes	1,583	1,440	1,900	2,226
Miscellaneous expenses	0	0	0	0
Net cash from operations	4,066	5,654	5,570	6,159
Capital expenditure	-2,934	-1,800	-1,800	-1,200
Change in Investments	50	0	0	0
Net cash from investing	-2,883	-1,800	-1,800	-1,200
Increase/Decrease in debt	1,615	-700	-700	-700
Dividends	-264	-264	-264	-264
Interest	-457	-454	-412	-370
Others	-120	0	-0	0
Net cash from financing	774	-1,417	-1,375	-1,333
Net Inc./(Dec.) in Cash	1,957	2,437	2,395	3,625
Opening cash balance	6,278	8,235	10,672	13,067
Closing cash balance	8,235	10,672	13,067	16,693

Source: Company, Axis Securities Research


Ratio Analysis

(%)

Y/E Mar, Rs Cr	FY25	FY26E	FY27E	FY28E
Sales growth	9.4	8.2	11.4	12.2
OPM	20.8	22.0	22.5	22.9
Oper. profit growth	12.7	14.7	14.0	14.2
COGS / Net sales	41.1	42.0	42.0	42.0
Overheads/Net sales	38.2	36.0	35.5	35.1
Depreciation / G. block	8.1	8.0	8.0	8.0
Effective interest rate	31.2	25.0	28.0	28.0
Net wkg.cap / Net sales	41.7	41.2	41.3	41.3
Net sales / Gr block (x)	1.6	1.5	1.6	1.7
RoCE	15.5	17.8	19.8	22.6
Debt/equity (x)	0.3	0.2	0.2	0.1
Effective tax rate	31.2	25.0	28.0	28.0
RoE	10.7	11.8	11.8	12.2
Payout ratio (Div/NP)	4.5	4.5	4.5	4.5
EPS (Rs)	60.0	74.4	84.1	98.6
EPS Growth	9.9	24.0	13.1	17.2
CEPS (Rs)	88.4	105.0	117.2	133.3
DPS (Rs)	4.5	4.5	4.5	4.5

Source: Company, Axis Securities Research

Aurobindo Pharma Price Chart and Recommendation History



Date	Reco	TP	Research
09-Nov-23	BUY	1,100	Result Update
12-Feb-24	BUY	1,170	Result Update
02-May-24	BUY	1,265	Top Picks
27-May-24	BUY	1,320	Result Update
03-Jun-24	BUY	1,320	Top Picks
01-Jul-24	BUY	1,330	Top Picks
01-Aug-24	BUY	1,650	Top Picks
12-Aug-24	BUY	1,612	Result Update
02-Sep-24	BUY	1,650	Top Picks
01-Oct-24	BUY	1,730	Top Picks
04-Nov-24	BUY	1,730	Top Picks
11-Nov-24	BUY	1,460	Result Update
02-Dec-24	BUY	1,730	Top Picks
01-Jan-25	BUY	1,500	Top Picks
10-Feb-25	BUY	1,500	Result Update
28-May-25	BUY	1,500	Result Update
06-Aug-25	BUY	1,400	Result Update

Source: Axis Securities Research

DISCLAIMER:

Axis Securities Limited is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.

Axis Securities Limited, is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with Securities and Exchange Board of India
- Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No.- NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No.- INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073| PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name – Mr. Rajiv Kejriwal, Tel No. – 022-68555574, Email id – compliance.officer@axisdirect.in;

Registered Office Address – Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai – 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parc, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances please call us at 022-40508080 or write to us helpdesk@axisdirect.in.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories etc. have conducted the routine inspection and based on their observations have issued advise/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in normal course of business, as a Stock Broker / Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and / or USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Axis Securities or its associates or its analysts did not receive

any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and / or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Research Analyst may have served as an officer, director or employee of subject company(ies). Axis Securities or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. This should not be construed as invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation.

RATING SCALE: Definitions of ratings

Ratings	Expected absolute returns over 12 – 18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward looking estimates for the stock, but we refrain from assigning valuation and recommendation.
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward-looking estimates, valuation or recommendation for the stock

Note: Returns stated in the rating scale are our internal benchmark.